Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

This study is testing whether a single dose of durvalumab (an immunotherapy drug) given before surgery can improve outcomes in women with early-stage triple-negative breast cancer (TNBC) — a type of breast cancer that lacks the three most common receptors and is typically harder to treat. **You may be eligible if...** - You are a woman aged 18 or older - You have been newly diagnosed with stage I triple-negative breast cancer (ER less than 10%, PR less than 10%, HER2 negative) - Your tumor has immune cells present (tumor infiltrating lymphocytes, or TILs, of 5% or more) - Your tumor is small (stage I, T1N0) with no spread to lymph nodes - You have not received any prior treatment for this cancer - Your blood counts and organ function are within required levels **You may NOT be eligible if...** - You have had prior systemic cancer therapy or radiation for this breast cancer - You have a known allergy to durvalumab - You have had an organ transplant or stem cell transplant - You have active autoimmune disease, HIV infection, or pulmonary fibrosis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.